Literature DB >> 12574005

Enalapril attenuates endothelin-1-induced hypertension via increased kinin survival.

Ahmed A Elmarakby1, Peter Morsing, David M Pollock.   

Abstract

Recent studies have shown that angiotensin-converting enzyme (ACE) inhibitors attenuate endothelin-1 (ET-1)-induced hypertension, but the mechanisms for this effect have not been clarified. Initial experiments were conducted to contrast the effect of the ACE inhibitor enalapril, the combined ACE-neutral endopeptidase inhibitor omapatrilat, and the angiotensin II receptor antagonist candesartan on the hypertensive and renal response to ET-1 in anesthetized Sprague-Dawley rats. Acute intravenous infusion of ET-1 (10 pmol x kg(-1) x min(-1)) for 60 min significantly increased mean arterial pressure (MAP) from 125 +/- 8 to 145 +/- 8 mmHg (P < 0.05) and significantly decreased glomerular filtration rate (GFR) from 0.31 +/- 0.09 to 0.13 +/- 0.05 ml x min(-1) x 100 g kidney wt(-1). Pretreatment with enalapril (10 mg/kg iv) before ET-1 infusion inhibited the increase in MAP (121 +/- 4 vs. 126 +/- 4 mmHg) before and during ET-1 infusion, respectively (P < 0.05) without blocking the effect of ET-1 on GFR. In contrast, neither omapatrilat (30 mg/kg) nor candesartan (10 mg/kg) had any effect on ET-1-induced increases in MAP or decreases in GFR. To determine whether the effect of enalapril was due to the decrease in angiotensin II or increase in kinin formation, rats were given REF-000359 (1 mg/kg iv), a selective B(2) receptor antagonist, with or without enalapril before ET-1 infusion. REF-000359 completely blocked the effect of enalapril on ET-1 infusion (MAP was 117 +/- 5 vs. 135 +/- 5 mmHg before and during ET-1 infusion, respectively, P < 0.05). REF-000359 alone had no effect on the response to ET-1 infusion (MAP was 117 +/- 4 vs. 144 +/- 4 mmHg before and during ET-1 infusion, respectively, P < 0.05). REF-000359 with or without enalapril had no significant effect on the ability of ET-1 infusion to decrease GFR. These findings support the hypothesis that decreased catabolism of bradykinin and its subsequent vasodilator activity oppose the actions of ET-1 to increase MAP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574005     DOI: 10.1152/ajpheart.00027.2003

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  5 in total

1.  Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension.

Authors:  Ahmed A Elmarakby; Jan M Williams; John D Imig; Jennifer S Pollock; David M Pollock
Journal:  Vascul Pharmacol       Date:  2006-09-26       Impact factor: 5.773

2.  Deletion of AT1a (Angiotensin II Type 1a) Receptor or Inhibition of Angiotensinogen Synthesis Attenuates Thoracic Aortopathies in Fibrillin1C1041G/+ Mice.

Authors:  Jeff Z Chen; Hisashi Sawada; Dien Ye; Yuriko Katsumata; Masayoshi Kukida; Satoko Ohno-Urabe; Jessica J Moorleghen; Michael K Franklin; Deborah A Howatt; Mary B Sheppard; Adam E Mullick; Hong S Lu; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-08-19       Impact factor: 10.514

3.  Olmesartan improves endothelin-induced hypertension and oxidative stress in rats.

Authors:  Li Yao; Hiroyuki Kobori; Matlubur Rahman; Dale M Seth; Takatomi Shokoji; Yuyan Fan; Guo-Xing Zhang; Shoji Kimura; Youichi Abe; Akira Nishiyama
Journal:  Hypertens Res       Date:  2004-07       Impact factor: 3.872

Review 4.  Pre-treatment considerations in childhood hypertension due to chronic kidney disease.

Authors:  Wasiu Adekunle Olowu
Journal:  World J Nephrol       Date:  2015-11-06

5.  Non-endothelial endothelin counteracts hypoxic vasodilation in porcine large coronary arteries.

Authors:  Elise R Hedegaard; Edgaras Stankevicius; Ulf Simonsen; Ole Fröbert
Journal:  BMC Physiol       Date:  2011-05-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.